Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies
Pathogens · 2025
DOI: 10.3390/pathogens14050415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathogens, 2025. Verfasst von Vassiliki C Pitiriga und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Immunoglobulin G, SARS-CoV-2, COVID-19, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The effective management of vaccination schedules requires thorough knowledge of an individual’s immunoprotection level, including the interaction and persistence of immune responses at both the humoral and cellular levels following SARS-CoV-2 vaccination. This study aimed to investigate the potential relationship between the levels and duration of the SARS-CoV-2 T cell response and IgG measurements in a cohort of COVID-19-naive individuals who had received the SARS-CoV-2 vaccine.
Methods
We performed a retrospective descriptive analysis utilizing data retrieved from the electronic medical records of consecutive COVID-19-naive and vaccinated adult individuals who underwent COVID-19 immunity screening at a private healthcare center from September 2021 to September 2022. T cell response was evaluated using the IGRA methodology T-SPOT®.COVID (Oxford Immunotec, Abingdon, Oxfordshire, UK).
Results
A retrospective analysis was conducted on a cohort of 262 individuals, comprising 148 females (56.5%) and 114 males (43.5%), with ages ranging from 17 to 92 years (mean age: 59.47 ± 15.5 years). Among the participants, 216/262 (82.4%) tested negative for SARS-CoV-2 IgG antibodies (group A), while 46/262 (17.6%) tested positive (group B). No significant difference was observed between the two groups in the time period post vaccination, with the mean times after vaccination being 136.38 ± 78.68 days in group A and 140.6 ± 79.5 days in group B (T-test, p = 0.74). Among the two groups, a positive T cell reaction against the S antigen was reported in 132/216 (61.1%) participants in group A and 39/46 (84.8%) in group B (X2 test, p = 0.002). Additionally, individuals with a positive antibody response demonstrated statistically significant higher T SPOT results compared to those with undetectable antibody levels, with a mean SFC count of 125.70 for group A and 158.73 for group B (Mann–Whitney test, p = 0.006).
Conclusions
Our findings suggest that T cell immunity may persist even when antibodies are undetectable, highlighting the potential role of cellular immunity in providing protection against COVID-19 over time. Additionally, this study demonstrates a significant correlation between humoral and cellular immune response levels to SARS-CoV-2, suggesting that the activation of humoral immunity following SARS-CoV-2 vaccination is associated with higher levels of cellular immunity compared to individuals with undetectable antibody levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Street, 11527 Athens, Greece.
- Molecular Biology Unit, 1st Department of Obstetrics and Gynecology, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Bioiatriki Healthcare Group, Kifisias 132 and Papada Street, 11526 Athens, Greece.
ORCID-Profile: Vassiliki C Pitiriga, Myrto Papamentzelopoulou, Dimitris Nikoloudis, Athanasios Tsakris
Zitieren
APA
Pitiriga, V. C., Papamentzelopoulou, M., Nikoloudis, D., Saldari, C., Konstantinakou, K. E., Vasileiou, I. V., & Tsakris, A. (2025). Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies. Pathogens. https://doi.org/10.3390/pathogens14050415
Vancouver
Pitiriga VC, Papamentzelopoulou M, Nikoloudis D, Saldari C, Konstantinakou KE, Vasileiou IV, et al. Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies. Pathogens. 2025. doi:10.3390/pathogens14050415
BibTeX
@article{Pitiriga2025,
author = {Pitiriga, Vassiliki C and Papamentzelopoulou, Myrto and Nikoloudis, Dimitris and Saldari, Chrysa and Konstantinakou, Kanella E and Vasileiou, Irene V and Tsakris, Athanasios},
title = {Evaluating SARS-CoV-2 T Cell Immunity in COVID-19-Naive Vaccinated Individuals with and Without Spike Protein IgG Antibodies},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14050415}
}
EUVIMED